A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
| 대상 질환 | Glioblastoma, Glioblastoma Multiforme |
|---|---|
| 임상 단계 | 1상 |
| 스폰서 | Bryan Allen |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 16 명 |
| 중재(약물) | Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy, Temozolomide |
| 시작일 | 2023년 2월 28일 |
| 완료일 | 2025년 5월 13일 |
| 결과 공개일 | 2026년 7월 20일 |
요약
This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.
Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs)
| Cohort 1 | 2 Dose Limiting Toxicities |
|---|---|
| Cohort 2 | 0 Dose Limiting Toxicities |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed M — National Cancer Institute (NCI)